- Start
- Oct 29, 202670% CONFIDENCEfrom public.com
Eli Lilly Q3 2026 Earnings Call
- Lilly has not yet confirmed the date; Nasdaq's and Public's earnings calendars expect the third-quarter 2026 report on 29 October 2026, before the market opens, with analysts projecting about $9.81 of EPS against $7.02 a year earlier.[2][3]
- Lilly announces each date about two weeks ahead and holds the call at 10 a.m. Eastern: it confirmed the second-quarter date on 22 July for 5 August, and reported the third quarter of 2025 on 30 October 2025.[5][6]
- Second-quarter 2026 revenue rose 48% to $23.0 billion, with reported EPS of $7.94 and non-GAAP EPS of $8.38, both after $3.03 a share of acquired IPR&D charges.[1]
- Mounjaro sales grew 91% to $9.94 billion and Zepbound 46% to $4.93 billion, while the new obesity pill Foundayo added $98 million in its first quarter on sale.[1][4]
- The quarter will be judged against full-year guidance raised to $85-87 billion of revenue (from $82-85 billion), a 49.0-50.5% performance margin and non-GAAP EPS of $35.50-36.50, assuming about 894 million shares.[1]
- Lilly held 60.9% of the US obesity and diabetes drug market in the second quarter against Novo Nordisk's 38.8%, and plans to file retatrutide with the FDA in the first quarter of 2027.[1][4]
References 671% CONFIDENCE
The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.
- [1]50%prnewswire.com/news-releases/lilly-reports-second-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-continued-growth-and-pipeline-progress-302843165.htmlprnewswire.com· Posted Sep 23, 2026· Starts Oct 29, 2026· 20% of score
Lilly has not confirmed the date yet (no "Lilly confirms date and conference call for third-quarter 2026" release as of 22 Sep 2026; the Q2 one came out on 22 July for 5 August). Public.com[2] and Nasdaq[3] list the Q3 report as "expected" on 10/29/2026 "before market open", matching Lilly's pattern (Q3 2025 reported October 30, 2025) and its calls, which "will begin at 10 a.m. Eastern time" - so 29 Oct 2026, 10:00 ET (14:00 UTC), estimated until Lilly's confirmation release.
- [2]70%Eli Lilly (LLY) Earnings: Latest Report, Earnings Call & Financialspublic.com· Published Sep 22, 2026· Starts Oct 29, 2026 ✓· 20% of score
Earnings calendar: "expected to announce its next earnings report on 10/29/2026, with analysts projecting an EPS of $9.81"; next earnings call Oct. 29, 2026; history shows Q3 2025 on Oct 30, Q2 2026 on Aug 5, 2026. An expectation, not Lilly's confirmation.[1]
- [3]70%LLY Earnings Date (Nasdaq)api.nasdaq.com· Published Sep 22, 2026· 20% of score
Nasdaq/Zacks: "expected* to report earnings on 10/29/2026 before market open" for the quarter ending Sep 2026; consensus EPS $9.56 (4 analysts), $7.02 a year earlier.
- [4]85%Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surgecnbc.com· Published Aug 5, 2026· 17% of score
CNBC on the second quarter: beat on revenue and EPS, guidance raised to $85-87 billion, Mounjaro $9.94 billion, Zepbound $4.93 billion, Foundayo $98 million, 60.9% US obesity and diabetes share vs Novo's 38.8%.
- [5]80%Lilly confirms date and conference call for second-quarter 2026 financial results announcementprnewswire.com· Published Jul 22, 2026· 16% of score
Lilly's own pattern: released 22 July for results on 5 August 2026, with the conference call beginning at 10 a.m. Eastern time; the matching third-quarter release will confirm this pin's date.[1]
Suggest a correction
Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most.
